Proposal to list point of care testing devices supplied by Medtronic New Zealand Limited
What we’re proposing
Pharmac is seeking feedback on a proposal to list point of care testing equipment and consumable medical devices supplied by Medtronic New Zealand Limited (“Medtronic”) in Part III of Section H of the Pharmaceutical Schedule from 1 June 2025 through a non-exclusive provisional agreement.
Consultation closes at 4pm, Tuesday, 29th April 2025 and feedback can be emailed to tyson.edwards@pharmac.govt.nz
What would the effect be?
From 1 June 2025, point of care testing equipment and consumable medical devices supplied by Medtronic would be listed under in the Pharmaceutical Schedule under a national agreement for all Health New Zealand | Te Whatu Ora (“Health NZ”) hospitals to purchase under, subject to consultation and approval by Pharmac’s Board or delegate (“Agreement”).
The Agreement would not be for sole supply and Health NZ hospitals can continue to purchase other suppliers’ brands of point of care testing equipment and consumables.
The Agreement would supersede any existing Health NZ contracts with Medtronic for the medical devices included in the Agreement. Any medical device listed in the Pharmac Agreement and purchased by a Health NZ hospital, would be in accordance with the terms and conditions, including price, stated in the Agreement, effective from the date of listing on the Pharmaceutical Schedule.
Pricing for the medical devices in the Agreement, subject to any prior termination of the Agreement, would not be increased without prior consultation and approval by Pharmac.
Who we think will be interested
- Health NZ staff including but not limited to the following areas:
- Clinical Engineers and maintenance services
- Clinical Product Evaluators
- Laboratory staff
- Point of Care Testing Coordinators
- Point of Care Specialists
- Procurement and supply chain
- Suppliers and wholesalers
About these products
Point of care testing is the analysis of clinical specimens to provide medical laboratory test results near to the patient or at the site of patient care. Point of care testing may be performed by multiple users including but not limited to clinical staff. It has an important role in providing a rapid test result near to the patient which can be used for diagnosis or monitoring a treatment response and may be acted upon quickly to provide effective, quality patient care.
Why we’re proposing this
Pharmac issued a Registration of Interest (“ROI”) for:
The ROI was for non-exclusive national agreements for listing on the Pharmaceutical Schedule.
The ROI invited registrations of interest for the supply of medical devices where New Zealand Health Partnerships ("NZHP") has previously released Request for Proposal processes from suppliers for listing on the Pharmaceutical Schedule.
Pharmac has been working with suppliers to seek provisional agreements and this is the latest proposal to arise from this process.
Details about our proposal
Pharmac has entered into a provisional agreement with Medtronic for the supply of point of care testing equipment and consumable medical devices. The proposal would result in Pharmaceutical Schedule listings for 14 medical devices from the ‘ACT Plus System’ brand.
Further information, including pricing and contractual details, has been provided to Health NZ Procurement personnel. Clinicians interested in further detail on what this change means for their hospital should engage with the Health NZ Procurement team.
To provide feedback
Send us an email: tyson.edwards@pharmac.govt.nz by 4pm, Tuesday 29th April 2025.
All feedback received before the closing date will be considered by Pharmac’s Board (or its delegate) prior to making a decision on this proposal.
Your feedback may be shared
Feedback we receive is subject to the Official Information Act 1982 (OIA). Please be aware that we may need to share your feedback, including your identity, in response to an OIA request. This applies to anyone providing feedback, whether they are providing feedback themselves or for an organisation, in a personal or professional capacity.
We can only keep feedback confidential as allowed under the OIA and other related laws. If you want any part of your feedback treated as confidential, you need to tell us. Please let us know if you want to keep part of your feedback confidential, and why. Is it commercially sensitive, confidential or proprietary, or personal information? Clearly state this and tell us which parts of your feedback you want to keep confidential for these reasons. We will consider your request under our OIA requirements.